Editing Eli Lilly and Company (section)

== Revenue breakdown by segment ==
Human Healthcare: This segment generated $26.2 billion in revenue in 2022, accounting for 87% of the company's total revenue. The top-selling products in this segment were Trulicity, a diabetes drug, and Verzenio, a breast cancer drug.

[[File:Revenue growth %.png|center|thumb|619x619px]]
{| class="wikitable"
!Product
!Revenue Growth (USD millions)
|-
|Verzenio
|1133.6
|-
|Trulicity
|967.8
|-
|Jardiance
|575.3
|-
|Mounjaro
|482.5
|-
|Taltz
|269.2
|}
Animal Health: This segment generated $1.5 billion in revenue in 2022, accounting for 5% of the company's total revenue. The top-selling products in this segment were Prascend, a treatment for equine Cushing's disease, and Zyess, a treatment for glaucoma in dogs.


Biosimilars and Insulin: This segment generated $2.3 billion in revenue in 2022, accounting for 8% of the company's total revenue. The top-selling products in this segment were Basaglar, a biosimilar version of Lantus, and Humalog, an insulin analogue.


Eli Lilly's revenue from the Human Healthcare segment has been growing steadily in recent years, driven by the success of new products such as Trulicity and Verzenio. The Animal Health segment has also been growing, albeit at a slower pace. The Biosimilars and Insulin segment is still relatively small, but it is expected to grow in the coming years.


'''Revenue breakdown by market (2022):'''

[[File:Revenue by market pie chart .png|center|thumb|635x635px]]

* United States: The United States was Eli Lilly's largest market in 2022, generating '''$15.8 billion''' in revenue, or 56% of the company's total revenue.
* Europe: Europe was the second largest market for Eli Lilly in 2022, generating '''$6.7 billion''' in revenue, or 23% of the company's total revenue.
* Japan: Japan was the third largest market for Eli Lilly in 2022, generating $2.8 billion in revenue, or 9% of the company's total revenue.
* China: China was the fourth largest market for Eli Lilly in 2022, generating $1.7 billion in revenue, or 6% of the company's total revenue.
* Rest of the World: The Rest of the World (ROW) was the fifth largest market for Eli Lilly in 2022, generating $2.2 billion in revenue, or 7% of the company's total revenue.

{| class="wikitable"
!Market
!Revenue (in billions of USD)
!Percentage of total revenue
|-
|United States
|15.8
|56%
|-
|Europe
|6.7
|23%
|-
|Japan
|2.8
|9%
|-
|China
|1.7
|6%
|-
|Rest of the World
|2.2
|7%
|}


Eli Lilly's revenue from the United States has been declining in recent years, due to increasing competition from generic drugs. However, the company's revenue from Europe, Japan, and China has been growing. Eli Lilly is also expanding its presence in the ROW, particularly in emerging markets such as India and Brazil.


Overall, Eli Lilly is a global pharmaceutical company with a strong presence in the United States, Europe, Japan, and China. The company is well-positioned to continue growing in the years to come, driven by the expansion of its presence in emerging markets and the launch of new products.